Dr. Megan Hartranft is a Clinical Lead with the Clinical and Digital Solutions team, directing development of oncology and pharmacogenomic focused digital products.
Prior to joining Labcorp, Dr. Hartranft was a Field Medical Scientific Associate Director at Sanofi, in charge of training for the hematology-oncology medical science liaison team. Earlier as a practicing clinician, she established an oral chemotherapy education program and participated in interprofessional clinics at Rush University Cancer Center. She has also spent time in academia as the oncology faculty member at Rosalind Franklin University of Medicine and Health Sciences, where she maintains an adjunct appointment. Dr. Hartranft also maintains a clinical appointment at Siteman Cancer Center in St. Louis. She is active in several professional organizations, including her roles as Chair of the Hematology Oncology Pharmacy Association's Public Policy & Advocacy Committee as well as the Treasurer of the Missouri Society of Health System Pharmacy.
Areas of Support: Hematology, Molecular Oncology
Board Certifications: PharmD, BCOP
Publications:
- Hoch MA, Cousins K, Nartey R, Riley K, Hartranft M. Two cases of combination therapy with cetuximab, paclitaxel, and cisplatin for advanced head and neck cancer. J Oncol Pharm Pract. 2018 Oct;24(7):553-554. https://www.ncbi.nlm.nih.gov/pubmed/28764598
- Bogdanowicz BS, Hoch MA, Hartranft ME. Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer. J Oncol Pharm Pract. 2017 Apr;23(3):203-214. http://www.ncbi.nlm.nih.gov/pubmed/26911477
- Hartranft ME, Clemmons AB, DeRemer DL, Kota V. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. J Oncol Pharm Pract. 2015 Oct 14. http://www.ncbi.nlm.nih.gov/pubmed/26471738
- Hartranft ME, Regal RE. "Triple Phase" Budesonide Capsules for the Treatment of Olmesartan-Induced Enteropathy. Ann Pharmacother. 2014 Sept;48(9):1234-1237. http://www.ncbi.nlm.nih.gov/pubmed/24958492
- Clemmons AB, Hartranft ME, Kota V, Pantin J, Awan FT, Salman H, Jillella AP. Administration of anti-thymocyte globulin: a comparison of two protocols. Bone Marrow Transplant. 2014 Aug 4. https://www.ncbi.nlm.nih.gov/pubmed/25089593
- Hackett MJ, Joolakanti S, Hartranft ME, Guley PC, Cho MJ. A dicarboxylic fatty acid derivative of paclitaxel for albumin-assisted drug delivery. J Pharm Sci. 2012 Jun 6. https://www.ncbi.nlm.nih.gov/pubmed/22674061